Advances in pathogenesis and therapy of hemolytic uremic syndrome caused by shiga toxin-2

The oxidative stress inducedin vivoby Shiga toxin-2 contributes to the pathogenicity of haemolytic uraemic syndrome

(2013) S. A. Gomez et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Identification of a Peptide-Based Neutralizer That Potently Inhibits Both Shiga Toxins 1 and 2 by Targeting Specific Receptor-Binding Regions

(2013) Kazue Tsutsuki et al.   INFECTION AND IMMUNITY

Functional Capacity of Shiga-Toxin Promoter Sequences in Eukaryotic Cells

(2013) Leticia V. Bentancor et al.   PLoS One

Action of Shiga Toxin Type-2 and Subtilase Cytotoxin on Human Microvascular Endothelial Cells

(2013) María M. Amaral et al.   PLoS One

Prophage Induction Is Enhanced and Required for Renal Disease and Lethality in an EHEC Mouse Model

(2013) Jessica S. Tyler et al.   PLoS Pathogens

Effects of Antibiotics on Shiga Toxin 2 Production and Bacteriophage Induction by Epidemic Escherichia coli O104:H4 Strain

(2012) Martina Bielaszewska et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Risk Factors for the Hemolytic Uremic Syndrome in Children Infected With Escherichia coli O157:H7: A Multivariable Analysis

(2012) C. S. Wong et al.   CLINICAL INFECTIOUS DISEASES

The enemy within us: lessons from the 2011 EuropeanEscherichia coliO104:H4 outbreak

(2012) Helge Karch et al.   EMBO Molecular Medicine

Shiga toxin-producing Escherichia coli O157 : H7 shows an increased pathogenicity in mice after the passage through the gastrointestinal tract of the same host

(2012) R. J. Fernandez-Brando et al.   JOURNAL OF MEDICAL MICROBIOLOGY

Renal and neurological involvement in typical Shiga toxin-associated HUS

(2012) Howard Trachtman et al.   Nature Reviews Nephrology

A Comparison of Shiga-Toxin 2 Bacteriophage from Classical Enterohemorrhagic Escherichia coli Serotypes and the German E. coli O104:H4 Outbreak Strain

(2012) Chad R. Laing et al.   PLoS One

Manganese Blocks Intracellular Trafficking of Shiga Toxin and Protects Against Shiga Toxicosis

(2012) S. Mukhopadhyay et al.   SCIENCE

Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study

(2012) J. Menne et al.   BMJ-British Medical Journal

The Interactions of Human Neutrophils with Shiga Toxins and Related Plant Toxins: Danger or Safety?

(2012) Maurizio Brigotti   Toxins

Shiga toxin 2-induced intestinal pathology in infant rabbits is A-subunit dependent and responsive to the tyrosine kinase and potential ZAK inhibitor imatinib

(2012) Samuel M. Stone et al.   Frontiers in Cellular and Infection Microbiology

Lessons Learned From Outbreaks of Shiga Toxin Producing Escherichia coli

(2012) Susanne Hauswaldt et al.   Current Infectious Disease Reports

Chemokine Receptor CCR1 Disruption Limits Renal Damage in a Murine Model of Hemolytic Uremic Syndrome

(2011) Maria V. Ramos et al.   AMERICAN JOURNAL OF PATHOLOGY

Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome

(2011) A.-l. Stahl et al.   BLOOD

Characterisation of the Escherichia coli strain associated with an outbreak of haemolytic uraemic syndrome in Germany, 2011: a microbiological study

(2011) Martina Bielaszewska et al.   LANCET INFECTIOUS DISEASES

Shiga toxin 2 overexpression in Escherichia coli O157:H7 strains associated with severe human disease

(2011) Mahesh Neupane et al.   MICROBIAL PATHOGENESIS

Eculizumab in Severe Shiga-Toxin–Associated HUS

(2011) Anne-Laure Lapeyraque et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Glucosylceramide Synthase Inhibitor Protects Rats Against the Cytotoxic Effects of Shiga Toxin 2

(2011) CLAUDIA SILBERSTEIN et al.   PEDIATRIC RESEARCH

Human Intestinal Tissue and Cultured Colonic Cells Contain Globotriaosylceramide Synthase mRNA and the Alternate Shiga Toxin Receptor Globotetraosylceramide

(2010) S. D. Zumbrun et al.   INFECTION AND IMMUNITY

Shiga toxin-associated hemolytic uremic syndrome: pathophysiology of endothelial dysfunction

(2010) Carla Zoja et al.   PEDIATRIC NEPHROLOGY

Hemolytic uremic syndrome: pathogenesis and update of interventions

(2009) Marina S Palermo et al.   Expert Review of Anti-Infective Therapy

Shiga Toxin Activates Complement and Binds Factor H: Evidence for an Active Role of Complement in Hemolytic Uremic Syndrome

(2009) Dorothea Orth et al.   JOURNAL OF IMMUNOLOGY

Host and pathogen determinants of verocytotoxin-producing Escherichia coli -associated hemolytic uremic syndrome

(2009) Mohamed A Karmali   KIDNEY INTERNATIONAL

Verotoxin biology: molecular events in vascular endothelial injury

(2009) Tania N Petruzziello et al.   KIDNEY INTERNATIONAL

Macropinocytosis in Shiga toxin 1 uptake by human intestinal epithelial cells and transcellular transcytosis

(2008) Irina Malyukova et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

ZAK: a MAP3Kinase that transduces Shiga toxin- and ricin-induced proinflammatory cytokine expression

(2008) Dakshina M. Jandhyala et al.   CELLULAR MICROBIOLOGY

Shiga toxin-2 results in renal tubular injury but not thrombotic microangiopathy in heterozygous factor H-deficient mice

(2008) D. Paixão-Cavalcante et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Human Microbiota-Secreted Factors Inhibit Shiga Toxin Synthesis by Enterohemorrhagic Escherichia coli O157:H7

(2008) T. de Sablet et al.   INFECTION AND IMMUNITY

Inhibition of water absorption in human proximal tubular epithelial cells in response to Shiga toxin-2

(2008) Claudia Silberstein et al.   PEDIATRIC NEPHROLOGY